Genomic Health announces study establishing the utility of Oncotype DX in node-negative and node-positive breast cancer patients treated with aromatase inhibitors.

Genomic Health Inc announced findings from a European study demonstrating that the Oncotype DX Recurrence Score result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive breast cancer patients who are treated with the aromatase inhibitor anastrozole or with tamoxifen. Researchers from the Royal Marsden Hospital in London discussed results in an oral presentation at the 31st Annual San Antonio Breast Cancer Symposium. Oncotype DX is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early …